Relation between Insulin-like Growth Factor Type 1 Receptor Expression and Histopathological of Prostate Adenocarcinoma

Authors

  • Hermien Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Muhammad Husni Cangara Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Djumadi Achmad Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Mahmud Ghaznawie Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Andi Alfian Zainuddin Department of Public Health and Community, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Muhammad Naufal Zuhair Medical Education Study Program, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Upik Anderiani Miskad Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Keywords:

Insulin-like growth factor 1 receptor (IGF-1R), prostate adenocarcinoma, WHO Grup Grade

Abstract

Prostate cancer is one of the most common cancer worldwide, where South Sulawesi is included in four provinces with the highest prevalence of prostate cancer in Indonesia. Laboratorium Sentra Patologia Makassar (SDPM) stated that prostate cancer cases continue to rise each year. Insulin-like growth factor system (IGF) has a central role in growth regulation, apoptosis resistance, and malignant invasion in humans. Increasing expression and IGF-1R activity are known to contribute to several aspects of cancer progression, including carcinogenesis, tumorigenesis, metastasis, chemotherapy resistance, and transformation. These inventions show that IGF-1R could be a potential target for cancer treatment. However, until now, no data shows relative levels of IGF-1R expression in prostate cancer and there's no consensus about IGF-1R roles in metastasis. This study is purposed to know IGF-1R expression in adenocarcinoma prostate grading. The type of this research is an observational analytical study with cross-sectional methods. Samples are taken based on consecutive sampling of as many as 46 respondents. There is no significant difference between IGF-1R expression score and histopathological feature of prostate adenocarcinoma WHO Grup Grade (p score=0,088 p>0,05). In conclusion, there is no correlation between IGF-1R and WHO Grup Grade.

References

. Ferlay, J. (2018). “Estimating the global cancer incidence and mortality in 2018 : GLOBOCAN sources and methods.” International Journal of Cancer, 1–13. https://doi.org/10.1002/ijc.31937

. Humphrey, P. A., Amin, M. B., Berney, D. M., Billis, A., Cao D., Cheng L., … Van der Kwast, T. (2016). Acinar adenocarcinoma. In J. M. Eble, G. Sauter, J. I. Epstein, & I. A. Sesterhenn (Eds.), WHO classification of tumours of the urinary system and male genital organs (pp. 138–162). Lyon: IARC Press.

. Humphrey PA, Amin MB, Berney DM, Billis A, Cao D, Cheng L, et al. (2016). WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE WHO Blue Books : History TUMOURS OF THE PROSTATE. In Acinar adenocarcinoma (4th editio, pp. 135–183). Lyon Cedex 08, France: International Agency for Research on Cancer (IARC).

. S. K. Denduluri et al. (2015). “Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance,” Genes Dis, vol. 2, no. 1, pp. 13–25, Mar. 2015, doi: 10.1016/j.gendis.2014.10.004.

. A. Philippou, A. Armakolas, and M. Koutsilieris. (2013). “Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer,” Front Endocrinol (Lausanne), vol. 4, p. 31, Mar. 2013, doi: 10.3389/fendo.2013.00031.

. A. Arcaro. (2013). “Targeting the insulin-like growth factor-1 receptor in human cancer,” Front Pharmacol, vol. 4, p. 30, 2013, doi: 10.3389/fphar.2013.00030.

. J. Wu and E. Yu. (2014). “Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy,” Cancer Metastasis Rev, vol. 33, no. 0, pp. 607–617, Sep. 2014, doi: 10.1007/s10555-013-9482-0.

. Hellawell, G. O., Turner, G. D. H., Davies, D. R., Poulsom, R., Brewster, S. F., & Macaulay, V. M. (2002). Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Research, 62(10), 2942–2950.

. Epstein, J. I., & Lotan, T. L. (2015). The lower urinary tract and male genital system. In V. Kumar, A. K. Abbas, & J. C. Aster (Eds.), Robbins and Cotran pathologic basis of disease (Ninth, pp. 980–990). Philadelphia: Elsevier Saunders.

. Ahearn, T. U., Peisch, S., Pettersson, A., Ebot, E. M., Zhou, K., Graff, R. E., … Edward, L. (2018). Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 39(12), 1–18. https://doi.org/10.1093/carcin/bgy112/5079148

Downloads

Published

2021-12-17

How to Cite

Hermien, Muhammad Husni Cangara, Djumadi Achmad, Mahmud Ghaznawie, Andi Alfian Zainuddin, Muhammad Naufal Zuhair, & Upik Anderiani Miskad. (2021). Relation between Insulin-like Growth Factor Type 1 Receptor Expression and Histopathological of Prostate Adenocarcinoma. International Journal of Sciences: Basic and Applied Research (IJSBAR), 60(5), 124–131. Retrieved from https://gssrr.org/index.php/JournalOfBasicAndApplied/article/view/13505

Issue

Vol. 60 No. 5 (2021)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.